Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023...
Combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early...
Launches Global Partnership With Know Your Lemons, Will Ring Nasdaq Opening Bell for 17th TimeMARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #bcam--Hologic, Inc. (Nasdaq:...
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical...
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted...
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential...
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and...
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues...
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or...
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of...
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical...
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation...
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show...
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical...
Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX...
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage...